Physical dependence is one factor which tends to perpetuate compulsive drug use and addiction and is thus an important component of drug abuse liability. The overall goal of this on-going grant project is to characterize the initiation and early development of opioid physical dependence in humans and to better understand the mechanisms by which physical dependence develops and escalates. This continuation application will build logically on previous studies of acute dependence in order to better understand the role of pharmacological factors including intrinsic drug efficacy in determining the dependence potential of opioid drugs and to begin exploring interventions that might effectively modulate the processes of physical dependence development. The first study will determine whether buprenorphine, a long-acting opioid partial agonist with relatively low efficacy and high receptor affinity, produces less acute physical dependence than does methadone or LAAM. A second study will determine whether, as predicted by certain current theories of tolerance and dependence, naloxone precipitation effects differ for fentanyl, morphine and meperidine as a function of their differing potency/intrinsic efficacy characteristics. Two additional studies will determine whether methadone has higher intrinsic ability to produce acute dependence than does morphine when the drugs are tested at equianalgesic doses and under conditions that remove the influence of receptor occupancy duration. The final three studies proposed examine treatment interventions that might modulate the dependence development process. One study will determine whether treatment with low dose naloxone can interrupt the process of acute dependence development by partially resetting receptors. A second study will determine whether treatment with the opioid peptide dynorphin can reduce the intensity of withdrawal subsequently precipitated by antagonist challenge in an acute dependence model while the final proposed study will determine whether treatment with an NMDA antagonist such as dextromethorphan can modulate acute dependence. Overall, the proposed studies will provide new insights into how various mu active opioids differ in their intrinsic ability to produce physical dependence effects. This information will be useful for understanding the relative advantages and disadvantages of opioid analgesics and of treatment medications with regard to dependence liability. New information will also be obtained about malleability of the dependence development processes by examining pharmacological interventions thought to influence relevant neurochemical mechanisms. Thus, these studies, building logically on previous work of the project, should produce new information with considerable basic scientific value as well as clinical relevance for developing new treatments of opioid drug dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA004011-13
Application #
2713062
Study Section
Special Emphasis Panel (SRCD (27))
Project Start
1986-04-01
Project End
1999-05-31
Budget Start
1998-06-01
Budget End
1999-05-31
Support Year
13
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Becker, A B; Strain, E C; Bigelow, G E et al. (2001) Gradual dose taper following chronic buprenorphine. Am J Addict 10:111-21
Schuh, K J; Walsh, S L; Stitzer, M L (1999) Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology (Berl) 145:162-74
Eissenberg, T; Stitzer, M L; Bigelow, G E et al. (1999) Relative potency of levo-alpha-acetylmethadol and methadone in humans under acute dosing conditions. J Pharmacol Exp Ther 289:936-45
Greenwald, M K; Stitzer, M L (1998) Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine. Drug Alcohol Depend 53:17-30
Eissenberg, T; Johnson, R E; Bigelow, G E et al. (1997) Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend 45:81-91
Greenwald, M K; Stitzer, M L; Haberny, K A (1997) Human pharmacology of the opioid neuropeptide dynorphin A(1-13). J Pharmacol Exp Ther 281:1154-63
Greenwald, M K; June, H L; Stitzer, M L et al. (1996) Comparative clinical pharmacology of short-acting mu opioids in drug abusers. J Pharmacol Exp Ther 277:1228-36
Schuh, K J; Walsh, S L; Bigelow, G E et al. (1996) Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. J Pharmacol Exp Ther 278:836-46
Eissenberg, T; Greenwald, M K; Johnson, R E et al. (1996) Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther 276:449-59
June, H L; Stitzer, M L; Cone, E (1995) Acute physical dependence: time course and relation to human plasma morphine concentrations. Clin Pharmacol Ther 57:270-80

Showing the most recent 10 out of 20 publications